clinical trial · NCT04998669
Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma
Juan P. Alderuccio, MD·phase2·recruiting·n = 100
Follicular LymphomaLoncastuximab tesirineRituximab
brief summary
The purpose of this research is to see if Loncastuximab Tesirine in combination with Rituximab will result in higher complete response rate when given to treat follicular lymphoma.
started
Feb 11, 2022
primary completion
Aug 1, 2027
completion
Aug 1, 2030
last updated
Mar 23, 2026
official title
Phase 2, Single-arm, Open-label, Study of Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol